Allurion Technologies Inc. (ALUR)
OTCMKTS · Delayed Price · Currency is USD
0.3600
+0.0998 (38.36%)
At close: Mar 12, 2026
Allurion Technologies Revenue
Allurion Technologies had revenue of $2.66M in the quarter ending September 30, 2025, a decrease of -50.48%. This brings the company's revenue in the last twelve months to $17.21M, down -50.49% year-over-year. In the year 2024, Allurion Technologies had annual revenue of $32.11M, down -39.94%.
Revenue (ttm)
17.21M
Revenue Growth
-50.49%
P/S Ratio
0.26
Revenue / Employee
126.53K
Employees
137
Market Cap
4.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32.11M | -21.36M | -39.94% |
| Dec 31, 2023 | 53.47M | -10.74M | -16.73% |
| Dec 31, 2022 | 64.21M | 25.97M | 67.91% |
| Dec 31, 2021 | 38.24M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAllurion Technologies News
- 12 hours ago - Allurion Advances Plan to Regain Listing Compliance - Business Wire
- 1 day ago - Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy - Business Wire
- 6 days ago - NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR) - Business Wire
- 10 days ago - Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE - Business Wire
- 16 days ago - Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds - Business Wire
- 17 days ago - Allurion Receives U.S. FDA Approval - Business Wire
- 5 weeks ago - Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices - Business Wire
- 2 months ago - Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results - Business Wire